Abnormal Anterior Pituitary Hormone Levels and Possible Neuroendocrine Relationships in Females With Hand Osteoarthritis: A Pilot Study.

Abnormal Anterior Pituitary Hormone Levels and Possible Neuroendocrine Relationships in Females With Hand Osteoarthritis: A Pilot Study. | Research Square window.SnipcartSettings = { analytics: { enabled: false } }; (function() { var accessVector = localStorage.getItem('access_vector') || ''; window.dataLayer = window.dataLayer || []; if (accessVector) { window.dataLayer.push({ user: { profile: { profileInfo: { snid: accessVector } } } }); } })(); (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-K279D39R'); Browse Preprints In Review Journals COVID-19 Preprints AJE Video Bytes Research Tools Research Promotion AJE Professional Editing AJE Rubriq About Preprint Platform In Review Editorial Policies Our Team Advisory Board Help Center Sign In Submit a Preprint Cite Share Download PDF Research Article Abnormal Anterior Pituitary Hormone Levels and Possible Neuroendocrine Relationships in Females With Hand Osteoarthritis: A Pilot Study. Mario Newton Leitao Azevedo, Mario Vaisman, Ingrid Bandeira Moss, and 2 more This is a preprint; it has not been peer reviewed by a journal. https://doi.org/ 10.21203/rs.3.rs-5013072/v1 This work is licensed under a CC BY 4.0 License Status: Posted Version 1 posted You are reading this latest preprint version Abstract Background. Hand Osteoarthritis (HOA) presents genetic and hereditary characteristics and related to menopause with inflammatory symptoms. Aim. To evaluate the anterior pituitary and sexual hormonal profiles of climacteric women with HOA and identify the probable link with hypothalamic commitment of GnRH (Gonadotropin Releasing Hormone) and TRH (Thyrotropin Releasing Hormone). Methodology. A retrospective, controlled trial on climacteric females patients with HOA compared to healthy women, and all submitted to hormonal evaluation by RIA for estradiol (E2), progesterone (PRG), follicle-stimulating hormone (FSH), luteinizing hormone (LH), thyroid stimulating hormone (TSH), parathyroid stimulating hormone (PTH), growth hormone (GH), prolactin (PRL), adrenocorticotropic hormone (ACTH). Results. The groups were homogeneously related to age, menopause onset, and expected climacteric levels of E2, PRG, FSH, ACTH, GH, and PTH; the HOA group, without black patients (p<0.000), presented more abnormal tests than the controls (<0.0000) in 86.4% (95%CI67,2-96.4) of the sample, and related to low levels of LH in 40.9%(95%CI22.1-61.9) and FSH in 9.09%(CI95%1.5-26.9), 45.4%(CI95%25.8-60.1) patients with increased levels of TSH (p<0.000) and 31.8%(CI95%15.1-53.0) with high PRL levels (p = 0.04). The analysis of hypothalamic dependence demonstrated that 50.0% (CI95% 29.7-70.2) of the sample presented low LH/FSH levels related to GnRH and 77.2%(CI95%56.5-01.1) with TSH/PRL levels associated with TRH. Conclusion. The HOA patients exhibit more hormonal abnormalities than the control group, and trend to sub-clinical syndromes of hypothyroidism, hyperprolactinemia, and hypogonadism hypogonadotropic only related to LH and ovarian hormones, and these findings demonstrated a probable neuroendocrine participation in HOA physiopathology. General Practice Hand Osteoarthritis pituitary hormones sexual hormones neuroendocrine inflammation osteoarthritis Background Hands Osteoarthritis (HOA) is an idiopathic manifestation of cartilage degeneration related to menopause with inflammatory signs, and genetic and hereditary profiles, and unrelated to trauma or articular overload without systemic commitment, presented several major histocompatibility complex antigens, and characterized by the development of acute initial interphalangeal arthritis, mucinous and bone cysts, sclerosis, hyperostosis [ 1 , 2 , 3 ]. Previous studies demonstrated the relationship of 28:1 between females and males, and that females developed with high levels of estrogen, and presented significant prevalence of myoma, hysterectomy, dysfunctional gynecological hemorrhages, breast complaints, and overproduction of aggressive enzymes and inflammatory molecules [ 4 , 5 , 6 , 7 , 8 , 9 , 10 ]. The excess of estrogen harms the hypothalamic neurons and compromises the TRH (thyrotropin-releasing hormone) and GnRH (gonadotropin-releasing hormones) surges, and modifies the production of dopamine, gonadotropins, TSH, prolactin (PRL), harms the hypothalamic/ pituitary axis, and this neuroendocrine disturbance affects the tissular metabolism and predisposes to inflammatory development [ 10 , 11 , 12 ]. Our concern about this theme started with anecdotal observation in 1992 with a 52-year-old female with exacerbated clinical signs of menopause, anxiety, acute HOA symptoms, breast secretion, hyperprolactinemia without pituitary adenoma, and all symptoms improved after seven days of treatment with bromocriptine. Supported by this evidence, the authors elaborated a pilot project with menopausal women with HOA, compared to homogeneous healthy group, to study the pituitary and sexual hormone profiles and search for probable neuroendocrine abnormalities and the link with unexpected hormonal levels and sub-clinical endocrinological syndromes which participate for the degenerative and inflammatory syndrome without systemic commitment. Method Study design and patients. A retrospective controlled trial with the data from the registry of female outpatients with HOA compared to a homogeneous healthy group to evaluate the pituitary and gonad hormonal profiles. The project approved by the Research Ethics Committee, and all participants signed the written informed consent participants, and to be included in the project must followed the criteria for the HOA diagnose from the American College of Rheumatology diagnostic criteria, and typical articular inflammatory signs, natural menopause for more than one year, and clinical and radiological characteristics [ 13 ]. The exclusion criteria include menstruation, inflammatory rheumatic diseases, metabolic diseases, degenerative diseases, trauma, systemic clinical diseases, and the use of medications that interfere on the hormonal profile. The control group performed with healthy women without HOA, who filled the exclusion criteria and freely agreed to participate in the trial. The data collected and registered in routine care from January 1993 to March 1994 and extracted in 2022. Clinical and laboratory collection. The demographic data included sex, age, disease length, menopause age, HOA onset, and ethnicity. The hormonal levels measurement made in fasting blood samples obtained at 7:00 AM, performed through radio-immune assays (RIA) tests with monoclonal antibody CIS-RIA (Dosage Immunradiométrique - CIS bio international 1993), to evaluate the levels of estradiol (E2), progesterone (PRG), and anterior pituitary follicle-stimulating hormone (FSH), luteinizing hormone (LH), thyroid stimulating hormone (TSH), parathyroid stimulating hormone (PTH), growth hormone (GH), prolactin (PRL), adrenocorticotropic hormone (ACTH) [ 14 , 15 ]. The abnormal tests defined by increased values ​​above the highest limits of E2, PGR, TSH, PRL, GH, ACTH, PTH and decreased values ​​below the FSH and LH lower limits obtained from laboratory analysis compared to the method’s expected normal hormonal ranges for climacteric women: estradiol (E2) from 0 to 60pg / ml; progesterone (PRG) from 0 to 73 pg/ml; luteinizing hormone (LH) from 13 to 122 µUI / ml; follicle-stimulating hormone (FSH) from 25 to 162 µIU / ml; thyroid stimulating hormone (TSH) from 0.4 to 3.19 mUI / ml; prolactin (PRL) from 2.0 to 10 ng/ml; growth hormone (GH) from 0.0 to 3,2 ng/ml; adrenocorticotropic hormone (ACTH) from 0 to 50 UI / ml; parathyroid hormone (PTH) 0 to 1.3 ng/ml [ 14 , 15 ]. The trend for endocrinological syndromes in HOA patients obtained through the comparison with the data from epidemiological frequency of hypothyroidism 15.2%; hyperprolactinemia 16.1%; hypogonadism 100%; hyper gonadotropic hormones 100% (increased FSH 100%, increased LH 100%); hypogonadism hypogonadotropic 10% [ 14 , 15 ]. Statistical analysis. The rationale for the study is that healthy climacteric women present hypogonadism hypogonadotropic and HOA appears in 18% of all menopausal women, between 49 to 54 years, risk of 0.23 and a chance of 0.25 [ 17 , 18 ]. Continuous variables are expressed as proportion, percentage, mean, standard deviation (sd), median, and absolute numbers using Student's t-test. Categorical variables are expressed as proportions and percentages and compared by chi-square or Fisher's exact tests and the Student test. The sample size obtained from a rheumatological population of 2162 outpatients with 25 HOA patients who filled the exclusion criteria with an expected sample size of 15 patients (CI95% 9.4–22.2) in each group. The significance level is 95%, the statistical significance p < 0.05, and the beta error is 80%. n Results The study included twenty-two patients in the HOA group and eleven participants in the healthy control group. The groups were homogeneous related to age, sex, menopause onset, and time of menopause. The HOA group without black ethnicity, and with abnormal hormonal levels in 86.4% (67.2-96.4) patients, more in controls, p<0.00000 OR 1222 (CI95%71–20830), and related to low LH titles in 40.9% (CI95%22,1-61.9), p=0.001, OR 14.5(CI95%0.8-256), and high titles of TSH in 45,4% (CI95%25.8-66.1) of patients and more than in controls, p=0.01, OR17.5 (0.9-337), and higher tiles of PRL in 31.8% (CI95%15.1-53) than the controls, p=0.04 OR 9.8 (CI95% 0.5-192). The evaluation of the quantitative hormonal values from the patients and healthy controls demonstrated no differences related to LH, FSH, ACTH, GH, PTH, E2, PRG levels, but significant higher levels of TSH (p=0.03) and PRL (p=0.01) in the HOA group. The HOA patients presented significantly more abnormal hormonal tests 16,6% (CI95%13.2-24.0) than the healthy control group, p<0.0000 OR 134.5 (2.08-570), with 40.09% (CI95% 22.1 -61.9) with low level of LH, p<0.000, OR 138.3 (CI95% 8.3-2209), and high levels of TSH in 45.4% (CI95% 25.8-66.1), p<0.000 OR 162 ( CI95% 9.8-2695), and high titles of PRL in 31.8% (CI95%15.1-53.05), p<0.000 OR93.5 (CI95% 5.6-1556). The evaluation of the aggregate of abnormal hormone frequency related to hypothalamic hormones demonstrated significant higher percentage in HOA group with 50% (CI95% 29.7-70.2) (p<0.000) of the sample dependent on GnRH abnormalities with low levels of LH and FSH (p<0.000), and 77.2% (CI95% 56.5-91.1) related to TRH hormones with high levels of TSH, and PRL (p<0.000). Discussion The study demonstrated that 86.4% of the HOA sample presented more abnormal hormone levels than the controls (p = 0.03), and preponderance of white ethnicity that signals a probable genetic predisposition (Table 1 ). The quantitative hormonal analysis (Table 2) demonstrated more pituitary hormonal abnormalities in HOA patients related to higher titles of TSH (p = 0.03) and PRL (p = 0.01). The frequency of patients with abnormal results (Table 3 ) demonstrated that 16.6% (13.2–24.0) of the HOA group presented more hormonal tests than the controls (p < 0.0000), and dependent of low levels of LH (p < 0.0000), and high levels of TSH (p < 0.0000), and PRL (p < 0.0000), and trends for hypogonadism hypogonadotropic in 50% ( CI95% 29.7–70.2), hyperthyroidism in 45.4% (CI95% 25.8–66.1), and hyperprolactinemia in 31.8% (CI95%15.1-53.05). These results demonstrated significant increased frequency of hormonal syndromes in HOA patients even when compared to the expected frequency of climacteric women [ 12 , 13 , 14 , 15 ]. The sub-clinical syndromes of hypogonadism hypogonadotropic related to LH deficiency, hypothyroidism, and hyperprolactinemia were probably dependent from the damage on hypothalamic neurons which interfere on gonadotropin-releasing hormone (GnRH) and thyrotropin-releasing hormone (TRH) surges. These findings corroborated the previous endocrinological studies in HOA patients which demonstrated, in addition to genetic and hereditary profiles, the relationship between high estrogen levels, and hypothalamic neurons damages, and neuroendocrine misbalance on the hypothalamus-pituitary–gonads axis which modifies the dopamine, TRH, GnRH production and collaborates for cartilage inflammation and degeneration [ 16 , 18 , 17 , 19 , 20 , 21 ]. The results of the hormonal profile in the HOA sample presented expected climacteric gonads hormone levels, and normal high FSH levels, but not expected abnormal low LH levels and high TSH and PRL titles. The hormones, acting on cellular pathways in the metabolic tissular environment, are fundamental for the cartilage health, but also play an important role on the development of the degenerative syndrome. The estrogen before menopause presents an anabolic activity stimulating the chondrocytes to produce normal extracellular matrix (ECM) through the increased stimulation of the Transforming Growth Factor beta (TGFβ) activity, but after menopause changes to a catabolic profile through the TGFβ activity modification and restricts the chondrocyte proliferation in the epiphyseal plaque, increases the production of inflammatory molecules (Interleukin1/IL1, Tumor Necrosis Factor-alpha /TNF α) and enzymes, impairs the activity of platelet-derived growth factor (PDGF), inhibits the synthesis of proteoglycans (PGN), and changes the hydrophilic characteristics of the ECM [ 7 , 22 , 23 ]. The degenerative and inflammatory processes are depend of hormonal synergism, and demonstrated with the PRL, dependent of TRH function, which stimulates the T-lymphocyte reactivity, fibroblasts activity, synovial hyperplasia, neo-angiogenesis, production of catabolic enzymes, and chondrocyte apoptosis [20, 21, 22, 23 ]. The hyperprolactinemia inhibits the anabolic activities of the TGFβ/ Smad via the PRL / JAK2 pathway, and associated with the high levels of IL1 and TGFβ found on osteoarthritic cartilage, restricts the mesenchymal-epithelial transition and deteriorates the ECM [ 24 , 25 ]. Also related, the abnormal TRH activity modifies the pituitary feedback and the increased TSH level induce to a sub-clinical hypothyroidism related with tissular degeneration [ 11 , 21 ]. The hormonal balance is fundamental for the tissue homeostasis which is disrupted after menopause and characterized by low levels of sexual hormones and high levels of gonadotropins. These hormones presented synergic and antagonist association demonstrated by FSH and estradiol opposite actions on the cellular differentiation of bone marrow cells: the FSH favoring the osteoclast formation and inflammatory cell activation which harm the sub-chondral bone; and the estrogen stimulates osteoblast accumulation; but after menopause the high FSH and low estrogen levels intensify the sclerostin catabolic activity, a protein made by osteocytes which intensify the bone remodeling process, the osteoarthritis phenotype, the chondrocyte differentiation and apoptosis [ 26, 27, 28, 29, 30]. The FSH participates for the bone and cartilage instability through the activation of inflammatory characteristics increasing the population of monocytoid CD14 + RANK cells which activates the receptor NGFKβ ligand and the Macrophage Colony-Stimulating Factor (M-CSF) and the secretion of IL 8 [ 26 , 27 ]. The FSH also stimulates the production of the protein β-catenin, a transcriptional cellular and signaling factor, with increased levels in the osteoarthritic cartilage, which through harmful mutations and hyper-expression is associated with neoplasm (lung, breast, ovary, endometrium, liver, and bowel), and the canonical Wnt -frizzled-β-catenin pathway up-regulates the expression of follicle-stimulating hormone receptors (FSH r) interrupts the degradation of β-catenin and changes the TGFβ activity leading to an osteoarthritic like phenotype [ 31 , 32 ]. The Wnt/ β-catenin signaling also reduces the action of sclerostin, a protein expressed by SOST genes in osteocytes, and harms the cartilage and sub-chondral bone integrity, and this activity had been described in the development of erosive HOA, temporomandibular OA, facet OA, diffuse idiopathic skeletal hyperostosis (DISH), and spondyloarthritis (SpA) [ 33 ]. The chondrocyte dedifferentiation characterizes the shift of the cell phenotype from the normal chondrocyte shape toward a polygonal fibroblast-like phenotype [ 34 ]. This change to a modified active fibroblast phenotype is stimulated by FSH, without estrogen participation, and inhibits the cAMP/PKA and MKK4/JNK signaling pathways inducing to an abnormal ECM production and inflammatory response [ 34 , 35 , 36 , 37 ]. The OA presents inflammatory signs without systemic commitment which appear to be independent of CD3 activation [ 38 ]. Previous studies demonstrated the association of HOA with inflammasome, a cytosolic protein complex related to the NOD-like receptor pyrin domain containing 3 (NLRP3), and significantly present in the serum of patients with non-erosive HOA, which stimulates the production of IL1β, TNF α, IL18, TGFβ, reactive oxygen, MMP and participates for cartilage degeneration and synovial inflammation [ 39 , 40 ]. This protein is activated by low levels of estrogen and progesterone, related with menopause, and modifies the Epithelial-Mesenchymal Transition (EMT), up-regulates the TGFβ catabolic action, enhances the TGFβ / Smad pathway, and participates in osteoarthritic development [ 41 , 42 , 43 , 44 ]. These results infer the role of genetics and hereditary profile which influenced by the old age and hormonal misbalance participate on tissular derangement. The study had a limited sample size and new trials are necessary to prove the results, compare it with a male sample, relate to inflammatory activity, evaluate the hypothalamic neuroendocrine profile, and compare it with the posterior pituitary hormonal profile. Conclusion This sample of HOA climacteric patients with congenital and hereditary profiles presented normal climacteric low levels of E2 and PRG, normal climacteric high levels of FSH, and abnormal pituitary hormonal profile with low levels of LH, and high levels of TSH and PRL, and trend for subclinical hypothyroidism, hyperprolactinemia, and hypogonadism related to low levels of LH. Declarations Ethical approval and consent to participate. Not applicable. Consent for publication . Not applicable Funding. Not applicable. Availibity of data and materials. Not applicable. Competing interests. The authors declare any competing interests. Acknowledgement. Not applicable. Author information. Affiliation . Mario Newton Leitao Azevedo. Universidade Federal do Rio de Janeiro, Rodolpho Paulo Rocco St 255, ZIP Code 21941 617, Rio de Janeiro, Brazil. https://orcid.org/0000-0002-0229-698X. [email protected] Mario Vaisman, Universidade Federal do Rio de Janeiro, Rodolpho Paulo Rocco St 255, ZIP Code 21941 617, Rio de Janeiro, Brazil. [email protected] Ingrid Bandeira Moss, Universidade Federal do Rio de Janeiro, Rodolpho Paulo Rocco St 255, ZIP Code 21941 617, Rio de Janeiro, Brazil. [email protected] . Breno Valdetaro Bianchi, Universidade Federal do Rio de Janeiro, Rodolpho Paulo Rocco St 255, ZIP Code 21941 617, Rio de Janeiro, Brazil. [email protected] . Blanca Elena Rios Gomes Bica, Universidade Federal do Rio de Janeiro, Rodolpho Paulo Rocco St 255, ZIP Code 21941 617, Rio de Janeiro, Brazil. [email protected] . Contribution . M.N.L.A . made the study conception and design, wrote the main manuscript text, and is the corresponding author. [email protected] , https://orcid.org/0000-0002-0229-698X, M.V. made the study conception,I.B.M. and B.V.B data collection, B.E.R.G.B. revised the final version of the manuscript. All authors reviewed the manuscript.. References Myers DL, Brandt KD, Hellish JW et al (1990) Synovial inflammation in patients with early osteoarthritis of the knee. J Rheumatol 17:1662–1669 PMID: 20844242 Patrick M, Manhine A, Ward AM (1989) HLA – AB antigens and alfa one antitrypsin phenotypes in generalized osteoarthritis and erosive arthritis. Ann Rheum Dis 48:470–475 PMID: 2787142: PMCID: PMC1003790 Bodis G, Toth V, Schwting A (2018) The role of human leukocyte antigens (HLA) in autoimmune diseases. Rheumatol Th. http://doi.org/10.1007/s40744.018.00100.3 Felson DT, Osteoarthritis (1990) Curr Opin Rheumatol 2:301–308. 10.1097/00002281-199002020-00010 Koszyowka M, Goulka J, Ganko M, Jana B (2011) Long term of estradiol 17 alpha administration reduces population of neurons in the sympathetic chain ganglia supplying the ovary in adult gilts. Exp Mol Pathol. ; 91: 353–361. https://doi.org/10;1016/j.yexmp.2021.04.002 Spector TD, Campion GD (1989) Generalized osteoarthritis: a hormonally mediated disease. Ann Rheum Dis. ; 48:523–527. Doi.1136/ard.48.6.523 Chandler CL, Dessa FM (1991) The effects of estrogen on cartilage degradation using in vitro and in vivo models. Agents Actions 34:282–284. 10.1007/BF01993303.PMID:1793045 McCann SM, Kimura M, Wlczewska A, Rettori V, Yu WH (1998) Hypothalamic control of FSH and LH by FSH-RF, LHRH, Cytokines, Leptin, and Nitric Oxide. Neuroimmunomodulation 5:193–202. https://doi.org/10.1159/000026337 Chakravarty SD, Markenson JA (2014) Rheumatic manifestation of endocrine disease. Curr Op Rheumatol 25:37–47. 10.1097/BOR Adan N, Guzmán-Morales J, Ladesma – Coluna MG, Perales - Canales SI, Quintana – Stephano A et al (2013) Prolactin promotes cartilage survival and attenuates inflammation in arthritis. J Clin Inv 12:3902–3913. htpps://doi.org/10.1172/JCI69485 Meites J (1995) Age-dependent changes in brain neurotransmitters and their influence on neuroendocrine functions. In: Rossmanith WG, Scherbaun WA (eds) The Endocrinology of Aging. Reprint 2012. W de Gruyter. https://doi.org/10.1515/9783110876765 . Kauffman AS (2022) Neuroendocrine mechanism underlying estrogen positive feedback and LH surge. Front Neuro Sci. https://doi.org/10.3389/fnins.2022.9532252 Altman R, Alarcon G, Appelrouth D, Bloch D, Borestein D, Brandt K (1990) The American College of Rheumatology criteria for classification and reporting of hand osteoarthritis. Arthritis Rheum 33:1601–1610. 10.1002/art.1780331101.PMID:2242058 Dosage, Immunradiométrique – 1 CIS bio international 1993. Folder from the laboratory Dosage Immunradiométrique – 2 CIS bio international 1993. Folder from the laboratory Abha M, Mangal NS, Hyperprolactinemia J, Hum Reprod S (2013) ; 6: 168–175. PMID:24347090 PMCID: PMC38533872 10.4103/0974-1208.121400 Burger H (2008) The menopausal transition – endocrinology. J Sex Med 5:2266–2273 PMID: 186249962 Doi:. 10.1111/j.1743-6109.2008.00921.x Kazmi SRH, Can AS (2021) Jan. Luteinizing hormone deficiency. [Updated2020 Nov29]. In: Stat Pearls. Treasures Island (Fl): Stat Pearls Publishing; 2021 Sep 9. PMID: 322965890 Lawrence RC, Hochberg C, Arnet FC et al (1998) Estimates of prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum 16:778–799 PMID: 9588729. 10.1002/1529-0131199805)41:5<778 Neidhart M, Gay RE, Gay S (1999) Prolactin and prolactin-like polypeptides in rheumatoid arthritis. Biomed Pharmacol 53:218–227. 10.1016/S0753-3322(99)80091-2 Lean MC, Podell RM (1995) Bone and joint manifestations of hypothyroidism. Sem Arthritis Rheum 24:282–290. 10.1016/s0049-01729580030-7 Blaney Davidson EM, Van Kaan AP, Vitters EL et al (2015) TGF–beta is a potent inducer of nerve growth factor in articular cartilage via the alk5-smad2/3 pathway. Potential role in osteoarthritis-related pain? Osteoarthritis Cartilage 23:478–486. 10.1016/j.joca.2014.12.005 Blaney Davidson EM, Vitters EL, Van Den Berg WB, Van Der Kraan PM (2006) TGF beta-induced cartilage repair is maintained, but fibrosis is in the presence of smad7. Arthritis Res Ther 8:R65. 10.1186/ar1931 Bailey JP, Nieport KM, Herbst MP, Srivastava A, Serra RA, Horseman ND (2004) Prolactin and Transforming Growth Factor – β signaling exerts opposing effects on mammary gland morphogenesis, involution, and the Akt-forkhead pathway. Mol Endocrinol 18:1171–1184. https://doi.org/10.1210/me.2003-0345 Hachim IY, López-Ozuma V, Hachim MY, Lebrun JJ, Ali S (2019) Concomitant expression of prolactin receptor and TGF β receptors in breast cancer: association with less aggressive phenotype and favorable patient. Int J Mol Sci 20:1640–1652. https://doi:10.3390/ijms20071640 Arclawi M, Al-Kadi H, Rouzi A, Qari M (2011) Determinants of serum sclerostin in healthy and postmenopausal women. J Bone Min Res 26:2812–2822. 10.1002/jbmr.479 Malakhova NG, Dzgoeva FU, Remizov OV, Botsieva VH, Ikoeva ZR, Goloeva VG, Gireyeva EYu, Tsallagova LV, Gurina AE Estradiol and follicle-stimulating hormone imbalance associated with metabolism disturbance and cardiovascular complications in women with hemodialysis. https://doi.org/10.36485/1561-6274-2022-26-3-72-79 Bulenka-Todorova L, Zhivkova R, Markova M, Ivanoska K Follicle stimulating hormone and estradiol alter immune response in osteoarthritic mice oppositely. Int J Immunopathol Pharmacol 2021; Jan – Dec : 32: 10.1177/205873842110161 Liu Y, Zhang M, Kong K, Li J, Liu W, Fu Y, Xu J (2020) High follicle-stimulating hormone levels accelerated cartilage damage of knee osteoarthritis in post menopause women through the PI3K/AKT/NFK β pathway. FEBS Open bio 10:2235–2245. 10.1002/2211-5463.12975 Zhu M, Tang D, WU Q, Hao S, Chen M, Xie C et al (2009) Activation of beta-catenin signaling in articular chondrocytes leads to osteoarthritis-like phenotype in adult beta-catenin conditional activation mice. J Bone Min Res 24:12–21. 10.1359/jbmr.080901 Corr M (2008) Wnt-β-catenin signaling in the pathogenesis of osteoarthritis. Nat Clin Pract Rheumatol 4:550–556. https://doi.org/10.1038/ncprheum0904 Zhong C, Yiya W, Liu C, Jiang Y, Kang L (2022) Key promoter region on Wnt4 response to FSH and genetic effect on several production traits of its mutations in chicken. Genes. 13(10, 1774; https://doi.org/103390/genes13101774 Zhou Y, Wang T, Hamilton JL, Chen D (2017) Wnt/β-catenin signaling in osteoarthritis and other forms of arthritis. Curr Rheumatol Rep. ; 19:53. doi.10.1007/s11926-017-0679.2 Charlier E, Dereyer C, Ciregia F, Malaise O, Neuville S, Lenner Z, Malaise M, de Seny D (2019) Chondrocyte dedifferentiation and osteoarthritis. Biochem Pharmacol 65:49–65. 10.1016/j.bcp. 2019.02.36 Parte S, Bhartiya D, Manjramkar DD et al (2013) Stimulation of ovarian stem cells by follicle-stimulating hormone and essential fibroblast growth factor during cortical tissue culture. J Ovarian Res 6. https://doi.org/10.1186/1757-2215-620 Huan Z, Wang Y, Zhang M, Zhang X, Liu Y, Kong L, Xu J (2021) Follicle-stimulating hormone worsen osteoarthritis by causing inflammation and chondrocyte dedifferentiation. FEBS Open Bio 11:2292–2303. 10.1002/2211-5463.13238 Wang Y, Zhang M, Huan Z, Shao S, Zhabg Y, Kong D, Xu J (2021) FSH directly regulates chondrocyte dedifferentiation and cartilage development. J Endocrinol 248:193–206. https://doi.org/10.1530/LOE-20-039 Lopes FPP, Azevedo MNL, Marchiori E, Fonseca LMR, Souza SAL, Gutfilen B (2011) Use of 99mTc-anti-CD3 scintigraphy in the differential diagnosis of rheumatic diseases. Brit J Rheumatol 49:933–939. https://doi.org/10.1093/rheumatology/kep471 Fioravanti A, Tenti S, McAllister M, Chemally M et al (2019) Exploring the involvement of NLRP3 and IL- 1β in osteoarthritis of the hand: Results from a pilot study. Mediators Inflamm. https://doi.org/10.1155/2019/2363460 McAllister, Chemaly M, Eakin AJ, Gibson DS et al (2018) NLRP3 is a potentially novel biomarker for the management of osteoarthritis. Osteoarthr Cart 26:612–619. https://doi.org/10.1016/jcq.2018.02.901 Azlan A, Salamonsen LA, Hutchison J, Evans J (2020) Endometrial activation accompanies menstruation and may have implications for systemic inflammatory events of the menstrual cycle. Hum Reprod 35:1362–1376. https://doi.org/10.1093/humrep/deaa065 Wang X, Ma l, Ding Q-D, Zhang W-Y, Chen Y-G, Wu J-H, Zhang H-F, Guo X-L Microglial NLRP3 inflammasome activation-mediated inflammation promotes prolactinoma development. 2021. Endocr Relat Cancer ; 28:433–448. 10.1530/ERC-2110137 Alyaseer AAA, de Lima MHS, BragaTT (2020). The Role of NLRP3 Inflammasome Activation in the Epithelial to Mesenchymal Transition Process during Fibrosis. 2020. Front Immunol; 11: 883. doi.3389/firmmu.00883 Choi JY, Jo MW, Lee EY, Kim SE, Lee DY, Choi DS (2022) Inhibition of NLRP3 inflammasome by progesterone is attenuated by abnormal autophagy induction in endometriotic cyst stromal cells: implication for endometriosis. Mol Hum Repro; 28: gaac007.doi:1093/molehr/gaac007 Tables Tables 1 to 3 are available in the Supplementary Files section. Additional Declarations The authors declare no competing interests. Supplementary Files Tables.docx Cite Share Download PDF Status: Posted Version 1 posted You are reading this latest preprint version Research Square lets you share your work early, gain feedback from the community, and start making changes to your manuscript prior to peer review in a journal. As a division of Research Square Company, we’re committed to making research communication faster, fairer, and more useful. We do this by developing innovative software and high quality services for the global research community. Our growing team is made up of researchers and industry professionals working together to solve the most critical problems facing scientific publishing. Also discoverable on Platform About Our Team In Review Editorial Policies Advisory Board Help Center Resources Author Services Accessibility API Access RSS feed Manage Cookie Preferences © Research Square 2026 | ISSN 2693-5015 (online) Privacy Policy Terms of Service Do Not Sell My Personal Information {"props":{"pageProps":{"initialData":{"identity":"rs-5013072","acceptedTermsAndConditions":true,"allowDirectSubmit":true,"archivedVersions":[],"articleType":"Research Article","associatedPublications":[],"authors":[{"id":347956072,"identity":"162602a1-0070-48c0-85d7-32700a2271b2","order_by":0,"name":"Mario Newton Leitao Azevedo","email":"data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAZAAAAAyAQMAAABI0h/eAAAABlBMVEX///8AAABVwtN+AAAACXBIWXMAAA7EAAAOxAGVKw4bAAAA4klEQVRIiWNgGAWjYBADxgaGg40PgAwePuK1MB5uNgBpYSNeC/PxNgkQi6AW3dnNjz98bLOR7Wc72Fb5NcdOho2B+eGjG3i0mN05ZmA4sy3NeGbPwbbbstuSgQ5jMzbOwaflRoJBMs+Zw4kbbgC1SG5jBmrhYZPGryX9w+E/Z/4nbrj/sK1Ycls9MVpyDJsZKg4kbjhwsI3x47bDRGkpZuypSDae2XCwWZpx23EeNmaCfknf/OGHgZ1sP8Pxhx9/bqu252dvfvgYnxYUwMwDJolVDgKMP0hRPQpGwSgYBSMGAADrrlCGhpr5CgAAAABJRU5ErkJggg==","orcid":"","institution":"Universidade Federal do Rio de Janeiro","correspondingAuthor":true,"prefix":"","firstName":"Mario","middleName":"Newton Leitao","lastName":"Azevedo","suffix":""},{"id":347956073,"identity":"ea5f1393-88b6-4a80-a413-719dcdb747ec","order_by":1,"name":"Mario Vaisman","email":"","orcid":"","institution":"Universidade Fedral do Rio de Janeiro","correspondingAuthor":false,"prefix":"","firstName":"Mario","middleName":"","lastName":"Vaisman","suffix":""},{"id":347956074,"identity":"36fe6659-e17e-4788-958c-3fa5f1aeebed","order_by":2,"name":"Ingrid Bandeira Moss","email":"","orcid":"","institution":"Universidade Fedral do Rio de Janeiro","correspondingAuthor":false,"prefix":"","firstName":"Ingrid","middleName":"Bandeira","lastName":"Moss","suffix":""},{"id":347956075,"identity":"7a943b4d-06fa-4bcf-8b01-ec9d68c9ca80","order_by":3,"name":"Breno Valdetaro Bianchi","email":"","orcid":"","institution":"Universidade Federal do Rio de Janeiro","correspondingAuthor":false,"prefix":"","firstName":"Breno","middleName":"Valdetaro","lastName":"Bianchi","suffix":""},{"id":347956076,"identity":"427135fa-5962-4a6b-a568-5f47a5b70fc3","order_by":4,"name":"Blance Elena Rios Gomes Bica","email":"","orcid":"","institution":"neiroUniversidade Federal do Rio de Janeiro","correspondingAuthor":false,"prefix":"","firstName":"Blance","middleName":"Elena Rios Gomes","lastName":"Bica","suffix":""}],"badges":[],"createdAt":"2024-09-01 13:19:52","currentVersionCode":1,"declarations":{"humanSubjects":true,"vertebrateSubjects":false,"conflictsOfInterestStatement":false,"humanSubjectEthicalGuidelines":true,"humanSubjectConsent":true,"humanSubjectClinicalTrial":true,"humanSubjectCaseReport":false,"vertebrateSubjectEthicalGuidelines":false},"doi":"10.21203/rs.3.rs-5013072/v1","doiUrl":"https://doi.org/10.21203/rs.3.rs-5013072/v1","draftVersion":[],"editorialEvents":[],"editorialNote":"","failedWorkflow":false,"files":[{"id":63951008,"identity":"d3dc9df9-001f-4fe2-afdc-fa98ec04be11","added_by":"auto","created_at":"2024-09-04 06:59:29","extension":"pdf","order_by":0,"title":"","display":"","copyAsset":false,"role":"manuscript-pdf","size":340235,"visible":true,"origin":"","legend":"","description":"","filename":"manuscript.pdf","url":"https://assets-eu.researchsquare.com/files/rs-5013072/v1/53cf399d-2b10-4ead-9092-568fbfb65429.pdf"},{"id":63950159,"identity":"27546d20-cecc-4a4f-85b0-1349127fa001","added_by":"auto","created_at":"2024-09-04 06:51:44","extension":"docx","order_by":1,"title":"","display":"","copyAsset":false,"role":"supplement","size":29304,"visible":true,"origin":"","legend":"","description":"","filename":"Tables.docx","url":"https://assets-eu.researchsquare.com/files/rs-5013072/v1/cc6a641663c53c2f0827cdfa.docx"}],"financialInterests":"The authors declare no competing interests.","formattedTitle":"\u003cp\u003eAbnormal Anterior Pituitary Hormone Levels and Possible Neuroendocrine Relationships in Females With Hand Osteoarthritis: A Pilot Study.\u003c/p\u003e","fulltext":[{"header":"Background","content":"\u003cp\u003eHands Osteoarthritis (HOA) is an idiopathic manifestation of cartilage degeneration related to menopause with inflammatory signs, and genetic and hereditary profiles, and unrelated to trauma or articular overload without systemic commitment, presented several major histocompatibility complex antigens, and characterized by the development of acute initial interphalangeal arthritis, mucinous and bone cysts, sclerosis, hyperostosis [\u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e, \u003cspan citationid=\"CR2\" class=\"CitationRef\"\u003e2\u003c/span\u003e, \u003cspan citationid=\"CR3\" class=\"CitationRef\"\u003e3\u003c/span\u003e]. Previous studies demonstrated the relationship of 28:1\u003c/p\u003e \u003cp\u003ebetween females and males, and that females developed with high levels of estrogen, and presented significant prevalence of myoma, hysterectomy, dysfunctional gynecological hemorrhages, breast complaints, and overproduction of aggressive enzymes and inflammatory molecules [\u003cspan citationid=\"CR4\" class=\"CitationRef\"\u003e4\u003c/span\u003e, \u003cspan citationid=\"CR5\" class=\"CitationRef\"\u003e5\u003c/span\u003e, \u003cspan citationid=\"CR6\" class=\"CitationRef\"\u003e6\u003c/span\u003e, \u003cspan citationid=\"CR7\" class=\"CitationRef\"\u003e7\u003c/span\u003e, \u003cspan citationid=\"CR8\" class=\"CitationRef\"\u003e8\u003c/span\u003e, \u003cspan citationid=\"CR9\" class=\"CitationRef\"\u003e9\u003c/span\u003e, \u003cspan citationid=\"CR10\" class=\"CitationRef\"\u003e10\u003c/span\u003e]. The excess of estrogen harms the hypothalamic neurons and compromises the TRH (thyrotropin-releasing hormone) and GnRH (gonadotropin-releasing hormones) surges, and modifies the production of dopamine, gonadotropins, TSH, prolactin (PRL), harms the hypothalamic/ pituitary axis, and this neuroendocrine disturbance affects the tissular metabolism and predisposes to inflammatory development [\u003cspan citationid=\"CR10\" class=\"CitationRef\"\u003e10\u003c/span\u003e, \u003cspan citationid=\"CR11\" class=\"CitationRef\"\u003e11\u003c/span\u003e, \u003cspan citationid=\"CR12\" class=\"CitationRef\"\u003e12\u003c/span\u003e].\u003c/p\u003e \u003cp\u003eOur concern about this theme started with anecdotal observation in 1992 with a 52-year-old female with exacerbated clinical signs of menopause, anxiety, acute HOA symptoms, breast secretion, hyperprolactinemia without pituitary adenoma, and all symptoms improved after seven days of treatment with bromocriptine. Supported by this evidence, the authors elaborated a pilot project with menopausal women with HOA, compared to homogeneous healthy group, to study the pituitary and sexual hormone profiles and search for probable neuroendocrine abnormalities and the link with unexpected hormonal levels and sub-clinical endocrinological syndromes which participate for the degenerative and inflammatory syndrome without systemic commitment.\u003c/p\u003e "},{"header":"Method","content":"\u003cp\u003e \u003cem\u003eStudy design and patients.\u003c/em\u003e \u003c/p\u003e\u003cp\u003eA retrospective controlled trial with the data from the registry of female outpatients with HOA compared to a homogeneous healthy group to evaluate the pituitary and gonad hormonal profiles. The project approved by the Research Ethics Committee, and all participants signed the written informed consent participants, and to be included in the project must followed the criteria for the HOA diagnose from the American College of Rheumatology diagnostic criteria, and typical articular inflammatory signs, natural menopause for more than one year, and clinical and radiological characteristics [\u003cspan citationid=\"CR13\" class=\"CitationRef\"\u003e13\u003c/span\u003e]. The exclusion criteria include menstruation, inflammatory rheumatic diseases, metabolic diseases, degenerative diseases, trauma, systemic clinical diseases, and the use of medications that interfere on the hormonal profile. The control group performed with healthy women without HOA, who filled the exclusion criteria and freely agreed to participate in the trial. The data collected and registered in routine care from January 1993 to March 1994 and extracted in 2022.\u003c/p\u003e\u003cp\u003e \u003cem\u003eClinical and laboratory collection.\u003c/em\u003e \u003c/p\u003e\u003cp\u003eThe demographic data included sex, age, disease length, menopause age, HOA onset, and ethnicity. The hormonal levels measurement made in fasting blood samples obtained at 7:00 AM, performed through radio-immune assays (RIA) tests with monoclonal antibody CIS-RIA (Dosage Immunradiométrique - CIS bio international 1993), to evaluate the levels of estradiol (E2), progesterone (PRG), and anterior pituitary follicle-stimulating hormone (FSH), luteinizing hormone (LH), thyroid stimulating hormone (TSH), parathyroid stimulating hormone (PTH), growth hormone (GH), prolactin (PRL), adrenocorticotropic hormone (ACTH) [\u003cspan citationid=\"CR14\" class=\"CitationRef\"\u003e14\u003c/span\u003e, \u003cspan citationid=\"CR15\" class=\"CitationRef\"\u003e15\u003c/span\u003e]. The abnormal tests defined by increased values ​​above the highest limits of E2, PGR, TSH, PRL, GH, ACTH, PTH and decreased values ​​below the FSH and LH lower limits obtained from laboratory analysis compared to the method’s expected normal hormonal ranges for climacteric women: estradiol (E2) from 0 to 60pg / ml; progesterone (PRG) from 0 to 73 pg/ml; luteinizing hormone (LH) from 13 to 122 µUI / ml; follicle-stimulating hormone (FSH) from 25 to 162 µIU / ml; thyroid stimulating hormone (TSH) from 0.4 to 3.19 mUI / ml; prolactin (PRL) from 2.0 to 10 ng/ml; growth hormone (GH) from 0.0 to 3,2 ng/ml; adrenocorticotropic hormone (ACTH) from 0 to 50 UI / ml; parathyroid hormone (PTH) 0 to 1.3 ng/ml [\u003cspan citationid=\"CR14\" class=\"CitationRef\"\u003e14\u003c/span\u003e, \u003cspan citationid=\"CR15\" class=\"CitationRef\"\u003e15\u003c/span\u003e]. The trend for endocrinological syndromes in HOA patients obtained through the comparison with the data from epidemiological frequency of hypothyroidism 15.2%; hyperprolactinemia 16.1%; hypogonadism 100%; hyper gonadotropic hormones 100% (increased FSH 100%, increased LH 100%); hypogonadism hypogonadotropic 10% [\u003cspan citationid=\"CR14\" class=\"CitationRef\"\u003e14\u003c/span\u003e, \u003cspan citationid=\"CR15\" class=\"CitationRef\"\u003e15\u003c/span\u003e].\u003c/p\u003e\u003cp\u003e \u003cem\u003eStatistical analysis.\u003c/em\u003e The rationale for the study is that healthy climacteric women present hypogonadism hypogonadotropic and HOA appears in 18% of all menopausal women, between 49 to 54 years, risk of 0.23 and a chance of 0.25 [\u003cspan citationid=\"CR17\" class=\"CitationRef\"\u003e17\u003c/span\u003e, \u003cspan citationid=\"CR18\" class=\"CitationRef\"\u003e18\u003c/span\u003e]. Continuous variables are expressed as proportion, percentage, mean, standard deviation (sd), median, and absolute numbers using Student's t-test. Categorical variables are expressed as proportions and percentages and compared by chi-square or Fisher's exact tests and the Student test. The sample size obtained from a rheumatological population of 2162 outpatients with 25 HOA patients who filled the exclusion criteria with an expected sample size of 15 patients (CI95% 9.4–22.2) in each group. The significance level is 95%, the statistical significance p \u0026lt; 0.05, and the beta error is 80%. n\u003c/p\u003e"},{"header":"Results","content":"\u003cp\u003eThe study included twenty-two patients in the HOA group and eleven participants in the healthy control group.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eThe groups were homogeneous related to age, sex, menopause onset, and time of menopause. The HOA group without black ethnicity, and with abnormal hormonal levels in 86.4% (67.2-96.4) patients, more in controls, p\u0026lt;0.00000 OR 1222 (CI95%71\u0026ndash;20830), and related to low LH titles in 40.9% (CI95%22,1-61.9), p=0.001, OR 14.5(CI95%0.8-256), and high titles of TSH in 45,4% (CI95%25.8-66.1) of patients and more than in controls, p=0.01, OR17.5 (0.9-337), and higher tiles of PRL in 31.8% (CI95%15.1-53) than the controls, p=0.04 OR 9.8 (CI95% 0.5-192).\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eThe evaluation of the quantitative hormonal values from the patients and healthy controls demonstrated no differences related to LH, FSH, ACTH, GH, PTH, E2, PRG levels, but significant higher levels of TSH (p=0.03) and PRL (p=0.01) in the HOA group.\u003c/p\u003e\n\u003cp\u003eThe HOA patients presented significantly more abnormal hormonal tests 16,6% (CI95%13.2-24.0) than the healthy control group, p\u0026lt;0.0000 OR 134.5 (2.08-570), with 40.09% (CI95% 22.1 -61.9) with low level of LH, p\u0026lt;0.000, OR 138.3 (CI95% 8.3-2209), and high levels of TSH in 45.4% (CI95% 25.8-66.1), p\u0026lt;0.000 OR 162 ( CI95% 9.8-2695), and high titles of PRL in 31.8% (CI95%15.1-53.05), p\u0026lt;0.000 OR93.5 (CI95% 5.6-1556). The evaluation of the aggregate of abnormal hormone frequency related to hypothalamic hormones demonstrated significant higher percentage in HOA group with 50% (CI95% 29.7-70.2) (p\u0026lt;0.000) \u0026nbsp;of the sample dependent on GnRH abnormalities with low levels of LH and FSH (p\u0026lt;0.000), and 77.2% (CI95% 56.5-91.1) related to TRH hormones with high levels of TSH, and PRL (p\u0026lt;0.000).\u003c/p\u003e"},{"header":"Discussion","content":"\u003cp\u003eThe study demonstrated that 86.4% of the HOA sample presented more abnormal hormone levels than the controls (p\u0026thinsp;=\u0026thinsp;0.03), and preponderance of white ethnicity that signals a probable genetic predisposition (Table\u0026nbsp;\u003cspan class=\"InternalRef\"\u003e1\u003c/span\u003e). The quantitative hormonal analysis (Table\u0026nbsp;2) demonstrated more pituitary hormonal abnormalities in HOA patients related to higher titles of TSH (p\u0026thinsp;=\u0026thinsp;0.03) and PRL (p\u0026thinsp;=\u0026thinsp;0.01). The frequency of patients with abnormal results (Table\u0026nbsp;\u003cspan class=\"InternalRef\"\u003e3\u003c/span\u003e) demonstrated that 16.6% (13.2\u0026ndash;24.0) of the HOA group presented more hormonal tests than the controls (p\u0026thinsp;\u0026lt;\u0026thinsp;0.0000), and dependent of low levels of LH (p\u0026thinsp;\u0026lt;\u0026thinsp;0.0000), and high levels of TSH (p\u0026thinsp;\u0026lt;\u0026thinsp;0.0000), and PRL (p\u0026thinsp;\u0026lt;\u0026thinsp;0.0000), and trends for hypogonadism hypogonadotropic in 50% ( CI95% 29.7\u0026ndash;70.2), hyperthyroidism in 45.4% (CI95% 25.8\u0026ndash;66.1), and hyperprolactinemia in 31.8% (CI95%15.1-53.05). These results demonstrated significant increased frequency of hormonal syndromes in HOA patients even when compared to the expected frequency of climacteric women [\u003cspan class=\"CitationRef\"\u003e12\u003c/span\u003e, \u003cspan class=\"CitationRef\"\u003e13\u003c/span\u003e, \u003cspan class=\"CitationRef\"\u003e14\u003c/span\u003e, \u003cspan class=\"CitationRef\"\u003e15\u003c/span\u003e].\u003c/p\u003e\n\u003cp\u003eThe sub-clinical syndromes of hypogonadism hypogonadotropic related to LH deficiency, hypothyroidism, and hyperprolactinemia were probably dependent from the damage on hypothalamic neurons which interfere on gonadotropin-releasing hormone (GnRH) and thyrotropin-releasing hormone (TRH) surges. These findings corroborated the previous endocrinological studies in HOA patients which demonstrated, in addition to genetic and hereditary profiles, the relationship between high estrogen levels, and hypothalamic neurons damages, and neuroendocrine misbalance on the hypothalamus-pituitary\u0026ndash;gonads axis which modifies the dopamine, TRH, GnRH production and collaborates for cartilage inflammation and degeneration [\u003cspan class=\"CitationRef\"\u003e16\u003c/span\u003e, \u003cspan class=\"CitationRef\"\u003e18\u003c/span\u003e, \u003cspan class=\"CitationRef\"\u003e17\u003c/span\u003e, \u003cspan class=\"CitationRef\"\u003e19\u003c/span\u003e, \u003cspan class=\"CitationRef\"\u003e20\u003c/span\u003e, \u003cspan class=\"CitationRef\"\u003e21\u003c/span\u003e].\u003c/p\u003e\n\u003cp\u003eThe results of the hormonal profile in the HOA sample presented expected climacteric gonads hormone levels, and normal high FSH levels, but not expected abnormal low LH levels and high TSH and PRL titles.\u003c/p\u003e\n\u003cp\u003eThe hormones, acting on cellular pathways in the metabolic tissular environment, are fundamental for the cartilage health, but also play an important role on the development of the degenerative syndrome. The estrogen before menopause presents an anabolic activity stimulating the chondrocytes to produce normal extracellular matrix (ECM) through the increased stimulation of the Transforming Growth Factor beta (TGF\u0026beta;) activity, but after menopause changes to a catabolic profile through the TGF\u0026beta; activity modification and restricts the chondrocyte proliferation in the epiphyseal plaque, increases the production of inflammatory molecules (Interleukin1/IL1, Tumor Necrosis Factor-alpha /TNF \u0026alpha;) and enzymes, impairs the activity of platelet-derived growth factor (PDGF), inhibits the synthesis of proteoglycans (PGN), and changes the hydrophilic characteristics of the ECM [\u003cspan class=\"CitationRef\"\u003e7\u003c/span\u003e, \u003cspan class=\"CitationRef\"\u003e22\u003c/span\u003e, \u003cspan class=\"CitationRef\"\u003e23\u003c/span\u003e]. The degenerative and inflammatory processes are depend of hormonal synergism, and demonstrated with the PRL, dependent of TRH function, which stimulates the T-lymphocyte reactivity, fibroblasts activity, synovial hyperplasia, neo-angiogenesis, production of catabolic enzymes, and chondrocyte apoptosis [20, 21, 22, 23\u003c/p\u003e\n\u003cp\u003e]. The hyperprolactinemia inhibits the anabolic activities of the TGF\u0026beta;/ Smad via the PRL / JAK2 pathway, and associated with the high levels of IL1 and TGF\u0026beta; found on osteoarthritic cartilage, restricts the mesenchymal-epithelial transition and deteriorates the ECM [\u003cspan class=\"CitationRef\"\u003e24\u003c/span\u003e, \u003cspan class=\"CitationRef\"\u003e25\u003c/span\u003e]. Also related, the abnormal TRH activity modifies the pituitary feedback and the increased TSH level induce to a sub-clinical hypothyroidism related with tissular degeneration [\u003cspan class=\"CitationRef\"\u003e11\u003c/span\u003e, \u003cspan class=\"CitationRef\"\u003e21\u003c/span\u003e].\u003c/p\u003e\n\u003cp\u003eThe hormonal balance is fundamental for the tissue homeostasis which is disrupted after menopause and characterized by low levels of sexual hormones and high levels of gonadotropins. These hormones presented synergic and antagonist association demonstrated by FSH and estradiol opposite actions on the cellular differentiation of bone marrow cells: the FSH favoring the osteoclast formation and inflammatory cell activation which harm the sub-chondral bone; and the estrogen stimulates osteoblast accumulation; but after menopause the high FSH and low estrogen levels intensify the sclerostin catabolic activity, a protein made by osteocytes which intensify the bone remodeling process, the osteoarthritis phenotype, the chondrocyte differentiation and apoptosis [ 26, 27, 28, 29, 30]. The FSH participates for the bone and cartilage instability through the activation of inflammatory characteristics increasing the population of monocytoid CD14\u0026thinsp;+\u0026thinsp;RANK cells which activates the receptor NGFK\u0026beta; ligand and the Macrophage Colony-Stimulating Factor (M-CSF) and the secretion of IL 8 [\u003cspan class=\"CitationRef\"\u003e26\u003c/span\u003e, \u003cspan class=\"CitationRef\"\u003e27\u003c/span\u003e]. The FSH also stimulates the production of the protein \u0026beta;-catenin, a transcriptional cellular and signaling factor, with increased levels in the osteoarthritic cartilage, which through harmful mutations and hyper-expression is associated with neoplasm (lung, breast, ovary, endometrium, liver, and bowel), and the canonical Wnt -frizzled-\u0026beta;-catenin pathway up-regulates the expression of follicle-stimulating hormone receptors (FSH r) interrupts the degradation of \u0026beta;-catenin and changes the TGF\u0026beta; activity leading to an osteoarthritic like phenotype [\u003cspan class=\"CitationRef\"\u003e31\u003c/span\u003e, \u003cspan class=\"CitationRef\"\u003e32\u003c/span\u003e]. The Wnt/ \u0026beta;-catenin signaling also reduces the action of sclerostin, a protein expressed by SOST genes in osteocytes, and harms the cartilage and sub-chondral bone integrity, and this activity had been described in the development of erosive HOA, temporomandibular OA, facet OA, diffuse idiopathic skeletal hyperostosis (DISH), and spondyloarthritis (SpA) [\u003cspan class=\"CitationRef\"\u003e33\u003c/span\u003e].\u003c/p\u003e\n\u003cp\u003eThe chondrocyte dedifferentiation characterizes the shift of the cell phenotype from the normal chondrocyte shape toward a polygonal fibroblast-like phenotype [\u003cspan class=\"CitationRef\"\u003e34\u003c/span\u003e]. This change to a modified active fibroblast phenotype is stimulated by FSH, without estrogen participation, and inhibits the cAMP/PKA and MKK4/JNK signaling pathways inducing to an abnormal ECM production and inflammatory response [\u003cspan class=\"CitationRef\"\u003e34\u003c/span\u003e, \u003cspan class=\"CitationRef\"\u003e35\u003c/span\u003e, \u003cspan class=\"CitationRef\"\u003e36\u003c/span\u003e, \u003cspan class=\"CitationRef\"\u003e37\u003c/span\u003e].\u003c/p\u003e\n\u003cp\u003eThe OA presents inflammatory signs without systemic commitment which appear to be independent of CD3 activation [\u003cspan class=\"CitationRef\"\u003e38\u003c/span\u003e]. Previous studies demonstrated the association of HOA with inflammasome, a cytosolic protein complex related to the NOD-like receptor pyrin domain containing 3 (NLRP3), and significantly present in the serum of patients with non-erosive HOA, which stimulates the production of IL1\u0026beta;, TNF \u0026alpha;, IL18, TGF\u0026beta;, reactive oxygen, MMP and participates for cartilage degeneration and synovial inflammation [\u003cspan class=\"CitationRef\"\u003e39\u003c/span\u003e, \u003cspan class=\"CitationRef\"\u003e40\u003c/span\u003e]. This protein is activated by low levels of estrogen and progesterone, related with menopause, and modifies the Epithelial-Mesenchymal Transition (EMT), up-regulates the TGF\u0026beta; catabolic action, enhances the TGF\u0026beta; / Smad pathway, and participates in osteoarthritic development [\u003cspan class=\"CitationRef\"\u003e41\u003c/span\u003e, \u003cspan class=\"CitationRef\"\u003e42\u003c/span\u003e, \u003cspan class=\"CitationRef\"\u003e43\u003c/span\u003e, \u003cspan class=\"CitationRef\"\u003e44\u003c/span\u003e]. These results infer the role of genetics and hereditary profile which influenced by the old age and hormonal misbalance participate on tissular derangement. The study had a limited sample size and new trials are necessary to prove the results, compare it with a male sample, relate to inflammatory activity, evaluate the hypothalamic neuroendocrine profile, and compare it with the posterior pituitary hormonal profile.\u003c/p\u003e"},{"header":"Conclusion","content":"\u003cp\u003eThis sample of HOA climacteric patients with congenital and hereditary profiles presented normal climacteric low levels of E2 and PRG, normal climacteric high levels of FSH, and abnormal pituitary hormonal profile with low levels of LH, and high levels of TSH and PRL, and trend for subclinical hypothyroidism, hyperprolactinemia, and hypogonadism related to low levels of LH.\u003c/p\u003e"},{"header":"Declarations","content":"\u003cp\u003e\u003cstrong\u003eEthical approval and consent to participate.\u003c/strong\u003e Not applicable.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eConsent for publication\u003c/strong\u003e. Not applicable\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eFunding.\u003c/strong\u003e\u0026nbsp; Not applicable.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eAvailibity of data and materials. \u0026nbsp;\u003c/strong\u003eNot applicable.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompeting interests.\u003c/strong\u003e The authors declare any competing interests.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eAcknowledgement.\u003c/strong\u003e Not applicable.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eAuthor information.\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eAffiliation\u003c/strong\u003e.\u003c/p\u003e\n\u003cp\u003eMario Newton Leitao Azevedo. Universidade Federal do Rio de Janeiro, Rodolpho Paulo Rocco St 255, ZIP Code 21941 617, Rio de Janeiro, Brazil. \u0026nbsp;https://orcid.org/0000-0002-0229-698X. [email protected]\u003c/p\u003e\n\u003cp\u003eMario Vaisman, Universidade Federal do Rio de Janeiro, Rodolpho Paulo Rocco St 255, ZIP Code 21941 617, Rio de Janeiro, Brazil. \u0026nbsp; [email protected]\u003c/p\u003e\n\u003cp\u003eIngrid Bandeira Moss, Universidade Federal do Rio de Janeiro, Rodolpho Paulo Rocco St 255, ZIP Code 21941 617, Rio de Janeiro, Brazil. [email protected].\u003c/p\u003e\n\u003cp\u003eBreno Valdetaro Bianchi, Universidade Federal do Rio de Janeiro, Rodolpho Paulo Rocco St 255, ZIP Code 21941 617, Rio de Janeiro, Brazil. \u0026nbsp;[email protected].\u003c/p\u003e\n\u003cp\u003eBlanca Elena Rios Gomes Bica, Universidade Federal do Rio de Janeiro, Rodolpho Paulo Rocco St 255, ZIP Code 21941 617, Rio de Janeiro, Brazil. \u0026nbsp;[email protected].\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eContribution\u003c/strong\u003e.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eM.N.L.A . made the study conception and design, wrote the main manuscript text, and is the corresponding author. [email protected], https://orcid.org/0000-0002-0229-698X, M.V. made the study conception,I.B.M. and B.V.B data collection, B.E.R.G.B. revised the final version of the manuscript. \u0026nbsp;All authors reviewed the manuscript..\u0026nbsp;\u003c/p\u003e"},{"header":"References","content":"\u003col\u003e\u003cli\u003e\u003cspan\u003eMyers DL, Brandt KD, Hellish JW et al (1990) Synovial inflammation in patients with early osteoarthritis of the knee. J Rheumatol 17:1662\u0026ndash;1669 PMID: 20844242\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003ePatrick M, Manhine A, Ward AM (1989) HLA \u0026ndash; AB antigens and alfa one antitrypsin phenotypes in generalized osteoarthritis and erosive arthritis. Ann Rheum Dis 48:470\u0026ndash;475 PMID: 2787142: PMCID: PMC1003790\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eBodis G, Toth V, Schwting A (2018) The role of human leukocyte antigens (HLA) in autoimmune diseases. Rheumatol Th. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttp://doi.org/10.1007/s40744.018.00100.3\u003c/span\u003e\u003cspan address=\"10.1007/s40744.018.00100.3\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eFelson DT, Osteoarthritis (1990) Curr Opin Rheumatol 2:301\u0026ndash;308. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1097/00002281-199002020-00010\u003c/span\u003e\u003cspan address=\"10.1097/00002281-199002020-00010\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eKoszyowka M, Goulka J, Ganko M, Jana B (2011) Long term of estradiol 17 alpha administration reduces population of neurons in the sympathetic chain ganglia supplying the ovary in adult gilts. Exp Mol Pathol. ; 91: 353\u0026ndash;361. https://doi.org/10;1016/j.yexmp.2021.04.002\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eSpector TD, Campion GD (1989) Generalized osteoarthritis: a hormonally mediated disease. Ann Rheum Dis. ; 48:523\u0026ndash;527. Doi.1136/ard.48.6.523\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eChandler CL, Dessa FM (1991) The effects of estrogen on cartilage degradation using in vitro and in vivo models. Agents Actions 34:282\u0026ndash;284. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1007/BF01993303.PMID:1793045\u003c/span\u003e\u003cspan address=\"10.1007/BF01993303.PMID:1793045\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eMcCann SM, Kimura M, Wlczewska A, Rettori V, Yu WH (1998) Hypothalamic control of FSH and LH by FSH-RF, LHRH, Cytokines, Leptin, and Nitric Oxide. Neuroimmunomodulation 5:193\u0026ndash;202. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1159/000026337\u003c/span\u003e\u003cspan address=\"10.1159/000026337\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eChakravarty SD, Markenson JA (2014) Rheumatic manifestation of endocrine disease. Curr Op Rheumatol 25:37\u0026ndash;47. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1097/BOR\u003c/span\u003e\u003cspan address=\"10.1097/BOR\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eAdan N, Guzm\u0026aacute;n-Morales J, Ladesma \u0026ndash; Coluna MG, Perales - Canales SI, Quintana \u0026ndash; Stephano A et al (2013) Prolactin promotes cartilage survival and attenuates inflammation in arthritis. J Clin Inv 12:3902\u0026ndash;3913. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehtpps://doi.org/10.1172/JCI69485\u003c/span\u003e\u003cspan address=\"htpps://10.1172/JCI69485\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eMeites J (1995) Age-dependent changes in brain neurotransmitters and their influence on neuroendocrine functions. In: Rossmanith WG, Scherbaun WA (eds) The Endocrinology of Aging. Reprint 2012. W de Gruyter. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1515/9783110876765\u003c/span\u003e\u003cspan address=\"10.1515/9783110876765\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eKauffman AS (2022) Neuroendocrine mechanism underlying estrogen positive feedback and LH surge. Front Neuro Sci. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.3389/fnins.2022.9532252\u003c/span\u003e\u003cspan address=\"10.3389/fnins.2022.9532252\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eAltman R, Alarcon G, Appelrouth D, Bloch D, Borestein D, Brandt K (1990) The American College of Rheumatology criteria for classification and reporting of hand osteoarthritis. Arthritis Rheum 33:1601\u0026ndash;1610. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1002/art.1780331101.PMID:2242058\u003c/span\u003e\u003cspan address=\"10.1002/art.1780331101.PMID:2242058\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eDosage, Immunradiom\u0026eacute;trique \u0026ndash; 1 CIS bio international 1993. Folder from the laboratory\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eDosage Immunradiom\u0026eacute;trique \u0026ndash; 2 CIS bio international 1993. Folder from the laboratory\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eAbha M, Mangal NS, Hyperprolactinemia J, Hum Reprod S (2013) ; 6: 168\u0026ndash;175. PMID:24347090 PMCID: PMC38533872 \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.4103/0974-1208.121400\u003c/span\u003e\u003cspan address=\"10.4103/0974-1208.121400\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eBurger H (2008) The menopausal transition \u0026ndash; endocrinology. J Sex Med 5:2266\u0026ndash;2273 PMID: 186249962 Doi:. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1111/j.1743-6109.2008.00921.x\u003c/span\u003e\u003cspan address=\"10.1111/j.1743-6109.2008.00921.x\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eKazmi SRH, Can AS (2021) Jan. Luteinizing hormone deficiency. [Updated2020 Nov29]. In: Stat Pearls. Treasures Island (Fl): Stat Pearls Publishing; 2021 Sep 9. PMID: 322965890\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eLawrence RC, Hochberg C, Arnet FC et al (1998) Estimates of prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum 16:778\u0026ndash;799 PMID: 9588729. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1002/1529-0131199805)41:5\u0026lt;778\u003c/span\u003e\u003cspan address=\"10.1002/1529-0131199805)41:5%3C778\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eNeidhart M, Gay RE, Gay S (1999) Prolactin and prolactin-like polypeptides in rheumatoid arthritis. Biomed Pharmacol 53:218\u0026ndash;227. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1016/S0753-3322(99)80091-2\u003c/span\u003e\u003cspan address=\"10.1016/S0753-3322(99)80091-2\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eLean MC, Podell RM (1995) Bone and joint manifestations of hypothyroidism. Sem Arthritis Rheum 24:282\u0026ndash;290. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1016/s0049-01729580030-7\u003c/span\u003e\u003cspan address=\"10.1016/s0049-01729580030-7\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eBlaney Davidson EM, Van Kaan AP, Vitters EL et al (2015) TGF\u0026ndash;beta is a potent inducer of nerve growth factor in articular cartilage via the alk5-smad2/3 pathway. Potential role in osteoarthritis-related pain? Osteoarthritis Cartilage 23:478\u0026ndash;486. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1016/j.joca.2014.12.005\u003c/span\u003e\u003cspan address=\"10.1016/j.joca.2014.12.005\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eBlaney Davidson EM, Vitters EL, Van Den Berg WB, Van Der Kraan PM (2006) TGF beta-induced cartilage repair is maintained, but fibrosis is in the presence of smad7. Arthritis Res Ther 8:R65. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1186/ar1931\u003c/span\u003e\u003cspan address=\"10.1186/ar1931\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eBailey JP, Nieport KM, Herbst MP, Srivastava A, Serra RA, Horseman ND (2004) Prolactin and Transforming Growth Factor \u0026ndash; β signaling exerts opposing effects on mammary gland morphogenesis, involution, and the Akt-forkhead pathway. Mol Endocrinol 18:1171\u0026ndash;1184. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1210/me.2003-0345\u003c/span\u003e\u003cspan address=\"10.1210/me.2003-0345\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eHachim IY, L\u0026oacute;pez-Ozuma V, Hachim MY, Lebrun JJ, Ali S (2019) Concomitant expression of prolactin receptor and TGF β receptors in breast cancer: association with less aggressive phenotype and favorable patient. Int J Mol Sci 20:1640\u0026ndash;1652. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi:10.3390/ijms20071640\u003c/span\u003e\u003cspan address=\"https://doi:10.3390/ijms20071640\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eArclawi M, Al-Kadi H, Rouzi A, Qari M (2011) Determinants of serum sclerostin in healthy and postmenopausal women. J Bone Min Res 26:2812\u0026ndash;2822. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1002/jbmr.479\u003c/span\u003e\u003cspan address=\"10.1002/jbmr.479\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eMalakhova NG, Dzgoeva FU, Remizov OV, Botsieva VH, Ikoeva ZR, Goloeva VG, Gireyeva EYu, Tsallagova LV, Gurina AE Estradiol and follicle-stimulating hormone imbalance associated with metabolism disturbance and cardiovascular complications in women with hemodialysis. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.36485/1561-6274-2022-26-3-72-79\u003c/span\u003e\u003cspan address=\"10.36485/1561-6274-2022-26-3-72-79\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eBulenka-Todorova L, Zhivkova R, Markova M, Ivanoska K Follicle stimulating hormone and estradiol alter immune response in osteoarthritic mice oppositely. Int J Immunopathol Pharmacol 2021; Jan \u0026ndash; Dec : 32: \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1177/205873842110161\u003c/span\u003e\u003cspan address=\"10.1177/205873842110161\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eLiu Y, Zhang M, Kong K, Li J, Liu W, Fu Y, Xu J (2020) High follicle-stimulating hormone levels accelerated cartilage damage of knee osteoarthritis in post menopause women through the PI3K/AKT/NFK β pathway. FEBS Open bio 10:2235\u0026ndash;2245. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1002/2211-5463.12975\u003c/span\u003e\u003cspan address=\"10.1002/2211-5463.12975\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eZhu M, Tang D, WU Q, Hao S, Chen M, Xie C et al (2009) Activation of beta-catenin signaling in articular chondrocytes leads to osteoarthritis-like phenotype in adult beta-catenin conditional activation mice. J Bone Min Res 24:12\u0026ndash;21. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1359/jbmr.080901\u003c/span\u003e\u003cspan address=\"10.1359/jbmr.080901\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eCorr M (2008) Wnt-β-catenin signaling in the pathogenesis of osteoarthritis. Nat Clin Pract Rheumatol 4:550\u0026ndash;556. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1038/ncprheum0904\u003c/span\u003e\u003cspan address=\"10.1038/ncprheum0904\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eZhong C, Yiya W, Liu C, Jiang Y, Kang L (2022) Key promoter region on Wnt4 response to FSH and genetic effect on several production traits of its mutations in chicken. Genes. 13(10, 1774; https://doi.org/103390/genes13101774\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eZhou Y, Wang T, Hamilton JL, Chen D (2017) Wnt/β-catenin signaling in osteoarthritis and other forms of arthritis. Curr Rheumatol Rep. ; 19:53. doi.10.1007/s11926-017-0679.2\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eCharlier E, Dereyer C, Ciregia F, Malaise O, Neuville S, Lenner Z, Malaise M, de Seny D (2019) Chondrocyte dedifferentiation and osteoarthritis. Biochem Pharmacol 65:49\u0026ndash;65. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1016/j.bcp. 2019.02.36\u003c/span\u003e\u003cspan address=\"10.1016/j.bcp. 2019.02.36\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eParte S, Bhartiya D, Manjramkar DD et al (2013) Stimulation of ovarian stem cells by follicle-stimulating hormone and essential fibroblast growth factor during cortical tissue culture. J Ovarian Res 6. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1186/1757-2215-620\u003c/span\u003e\u003cspan address=\"10.1186/1757-2215-620\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eHuan Z, Wang Y, Zhang M, Zhang X, Liu Y, Kong L, Xu J (2021) Follicle-stimulating hormone worsen osteoarthritis by causing inflammation and chondrocyte dedifferentiation. FEBS Open Bio 11:2292\u0026ndash;2303. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1002/2211-5463.13238\u003c/span\u003e\u003cspan address=\"10.1002/2211-5463.13238\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eWang Y, Zhang M, Huan Z, Shao S, Zhabg Y, Kong D, Xu J (2021) FSH directly regulates chondrocyte dedifferentiation and cartilage development. J Endocrinol 248:193\u0026ndash;206. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1530/LOE-20-039\u003c/span\u003e\u003cspan address=\"10.1530/LOE-20-039\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eLopes FPP, Azevedo MNL, Marchiori E, Fonseca LMR, Souza SAL, Gutfilen B (2011) Use of 99mTc-anti-CD3 scintigraphy in the differential diagnosis of rheumatic diseases. Brit J Rheumatol 49:933\u0026ndash;939. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1093/rheumatology/kep471\u003c/span\u003e\u003cspan address=\"10.1093/rheumatology/kep471\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eFioravanti A, Tenti S, McAllister M, Chemally M et al (2019) Exploring the involvement of NLRP3 and IL- 1β in osteoarthritis of the hand: Results from a pilot study. Mediators Inflamm. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1155/2019/2363460\u003c/span\u003e\u003cspan address=\"10.1155/2019/2363460\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eMcAllister, Chemaly M, Eakin AJ, Gibson DS et al (2018) NLRP3 is a potentially novel biomarker for the management of osteoarthritis. Osteoarthr Cart 26:612\u0026ndash;619. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1016/jcq.2018.02.901\u003c/span\u003e\u003cspan address=\"10.1016/jcq.2018.02.901\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eAzlan A, Salamonsen LA, Hutchison J, Evans J (2020) Endometrial activation accompanies menstruation and may have implications for systemic inflammatory events of the menstrual cycle. Hum Reprod 35:1362\u0026ndash;1376. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1093/humrep/deaa065\u003c/span\u003e\u003cspan address=\"10.1093/humrep/deaa065\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eWang X, Ma l, Ding Q-D, Zhang W-Y, Chen Y-G, Wu J-H, Zhang H-F, Guo X-L Microglial NLRP3 inflammasome activation-mediated inflammation promotes prolactinoma development. 2021. Endocr Relat Cancer ; 28:433\u0026ndash;448. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1530/ERC-2110137\u003c/span\u003e\u003cspan address=\"10.1530/ERC-2110137\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eAlyaseer AAA, de Lima MHS, BragaTT (2020). The Role of NLRP3 Inflammasome Activation in the Epithelial to Mesenchymal Transition Process during Fibrosis. 2020. Front Immunol; 11: 883. doi.3389/firmmu.00883\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eChoi JY, Jo MW, Lee EY, Kim SE, Lee DY, Choi DS (2022) Inhibition of NLRP3 inflammasome by progesterone is attenuated by abnormal autophagy induction in endometriotic cyst stromal cells: implication for endometriosis. Mol Hum Repro; 28: gaac007.doi:1093/molehr/gaac007\u003c/span\u003e\u003c/li\u003e\u003c/ol\u003e"},{"header":"Tables","content":"\u003cp\u003eTables 1 to 3 are available in the Supplementary Files section.\u003c/p\u003e"}],"fulltextSource":"","fullText":"","funders":[],"hasAdminPriorityOnWorkflow":false,"hasManuscriptDocX":true,"hasOptedInToPreprint":true,"hasPassedJournalQc":"","hasAnyPriority":true,"hideJournal":true,"highlight":"","institution":"Universidade Federal do Rio de Janeiro","isAcceptedByJournal":false,"isAuthorSuppliedPdf":false,"isDeskRejected":"","isHiddenFromSearch":false,"isInQc":false,"isInWorkflow":false,"isPdf":false,"isPdfUpToDate":true,"isWithdrawnOrRetracted":false,"journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true},"keywords":"Hand Osteoarthritis, pituitary hormones, sexual hormones, neuroendocrine, inflammation, osteoarthritis","lastPublishedDoi":"10.21203/rs.3.rs-5013072/v1","lastPublishedDoiUrl":"https://doi.org/10.21203/rs.3.rs-5013072/v1","license":{"name":"CC BY 4.0","url":"https://creativecommons.org/licenses/by/4.0/"},"manuscriptAbstract":"\u003cp\u003e\u003cstrong\u003eBackground.\u003c/strong\u003e \u0026nbsp;Hand Osteoarthritis (HOA) presents genetic and hereditary characteristics and related to menopause with inflammatory symptoms.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eAim.\u003c/strong\u003e To evaluate the anterior pituitary and sexual hormonal profiles of climacteric women with HOA and identify the probable link with hypothalamic commitment of GnRH (Gonadotropin Releasing Hormone) and TRH (Thyrotropin Releasing Hormone).\u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eMethodology.\u003c/strong\u003e \u0026nbsp;A retrospective, controlled trial on climacteric females patients with HOA compared to healthy women, and all submitted to hormonal evaluation by RIA for estradiol (E2), progesterone (PRG), follicle-stimulating hormone (FSH), luteinizing hormone (LH), thyroid stimulating hormone (TSH), parathyroid stimulating hormone (PTH), growth hormone (GH), prolactin (PRL), adrenocorticotropic hormone (ACTH). \u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eResults.\u003c/strong\u003e The groups were homogeneously related to age, menopause onset, and expected climacteric levels of E2, PRG, FSH, ACTH, GH, and PTH; the HOA group, without black patients (p\u0026lt;0.000), \u0026nbsp;presented more abnormal tests than the controls (\u0026lt;0.0000) in 86.4% (95%CI67,2-96.4) of the sample, and related to low levels of LH in 40.9%(95%CI22.1-61.9) and FSH in 9.09%(CI95%1.5-26.9), 45.4%(CI95%25.8-60.1) patients with increased levels of TSH (p\u0026lt;0.000) and 31.8%(CI95%15.1-53.0) with high PRL levels (p = 0.04). \u0026nbsp;The analysis of hypothalamic dependence demonstrated that 50.0% (CI95% 29.7-70.2) of the sample presented low LH/FSH levels related to GnRH and 77.2%(CI95%56.5-01.1) with TSH/PRL levels associated with TRH. \u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eConclusion.\u003c/strong\u003e The HOA patients exhibit more hormonal abnormalities than the control group, and trend to sub-clinical syndromes of hypothyroidism, hyperprolactinemia, and hypogonadism hypogonadotropic only related to LH and ovarian hormones, and these findings demonstrated a probable neuroendocrine participation in HOA physiopathology.\u003c/p\u003e","manuscriptTitle":"Abnormal Anterior Pituitary Hormone Levels and Possible Neuroendocrine Relationships in Females With Hand Osteoarthritis: A Pilot Study.","msid":"","msnumber":"","nonDraftVersions":[{"code":1,"date":"2024-09-04 06:51:24","doi":"10.21203/rs.3.rs-5013072/v1","editorialEvents":[{"type":"communityComments","content":0}],"status":"published","journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true}}],"origin":"","ownerIdentity":"cbffce4f-305a-4fa2-bb25-92590fda9ea2","owner":[],"postedDate":"September 4th, 2024","published":true,"recentEditorialEvents":[],"rejectedJournal":[],"revision":"","amendment":"","status":"posted","subjectAreas":[{"id":37065555,"name":"General Practice"}],"tags":[],"updatedAt":"2024-09-04T06:51:25+00:00","versionOfRecord":[],"versionCreatedAt":"2024-09-04 06:51:24","video":"","vorDoi":"","vorDoiUrl":"","workflowStages":[]},"version":"v1","identity":"rs-5013072","journalConfig":"researchsquare"},"__N_SSP":true},"page":"/article/[identity]/[[...version]]","query":{"redirect":"/article/rs-5013072","identity":"rs-5013072","version":["v1"]},"buildId":"qtupq5eGEP_6zYnWcrvyt","isFallback":false,"isExperimentalCompile":false,"dynamicIds":[84888],"gssp":true,"scriptLoader":[]}